Merit Medical Systems (MMSI) Aktienübersicht
Merit Medical Systems, Inc. entwirft, entwickelt, produziert und vermarktet medizinische Einwegprodukte für interventionelle, diagnostische und therapeutische Verfahren in den Vereinigten Staaten, China, Japan, Deutschland, Frankreich, dem Vereinigten Königreich und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 3/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
MMSI unsere Risikoprüfungen bestanden.
MMSI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Merit Medical Systems, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$83.35 |
| 52-Wochen-Hoch | US$94.75 |
| 52-Wochen-Tief | US$59.74 |
| Beta | 0.51 |
| 1 Monat Veränderung | 20.20% |
| 3 Monate Veränderung | 34.41% |
| 1 Jahr Veränderung | -1.78% |
| 3 Jahre Veränderung | 15.44% |
| 5 Jahre Veränderung | 24.42% |
| Veränderung seit IPO | 1,507.79% |
Aktuelle Nachrichten und Updates
MMSI: Lower P/E Assumptions Will Set Up Future Repricing Potential
The analyst price target for Merit Medical Systems has been reduced from about $118 to $110 as analysts incorporate a slightly lower assumed future P/E multiple, while maintaining modestly higher revenue growth and profit margin assumptions. Analyst Commentary Recent Street research on Merit Medical Systems has centered on lower price targets, but many reports still highlight constructive views on the company’s execution and long term opportunity set.
MMSI: Discount Rate Reset And 2026 Guidance Will Support Share Price
Analysts have trimmed their price targets on Merit Medical Systems by between $2 and $20, with the updated fair value estimate holding near $89.55 as they adjust assumptions around discount rates and valuation multiples while keeping revenue growth and profit margin expectations broadly unchanged. Analyst Commentary Recent Street research around Merit Medical Systems shows a cluster of reduced price targets, but the commentary behind those changes is more mixed.MMSI: Margin Strength And 2026 Guidance Reset Will Drive Future Upside
Merit Medical Systems' analyst price target has been reset lower by about $8.82 per share. This change reflects analysts' updated assumptions for slightly softer revenue growth, a modestly lower discount rate, stronger profit margins, and a reduced future P/E multiple.Recent updates
MMSI: Lower P/E Assumptions Will Set Up Future Repricing Potential
The analyst price target for Merit Medical Systems has been reduced from about $118 to $110 as analysts incorporate a slightly lower assumed future P/E multiple, while maintaining modestly higher revenue growth and profit margin assumptions. Analyst Commentary Recent Street research on Merit Medical Systems has centered on lower price targets, but many reports still highlight constructive views on the company’s execution and long term opportunity set.MMSI: Discount Rate Reset And 2026 Guidance Will Support Share Price
Analysts have trimmed their price targets on Merit Medical Systems by between $2 and $20, with the updated fair value estimate holding near $89.55 as they adjust assumptions around discount rates and valuation multiples while keeping revenue growth and profit margin expectations broadly unchanged. Analyst Commentary Recent Street research around Merit Medical Systems shows a cluster of reduced price targets, but the commentary behind those changes is more mixed.MMSI: Margin Strength And 2026 Guidance Reset Will Drive Future Upside
Merit Medical Systems' analyst price target has been reset lower by about $8.82 per share. This change reflects analysts' updated assumptions for slightly softer revenue growth, a modestly lower discount rate, stronger profit margins, and a reduced future P/E multiple.Oncology And Endoscopy Platforms Will Reshape Long Term Earnings Power
Catalysts About Merit Medical Systems Merit Medical Systems develops and sells medical devices used in vascular, oncology, cardiac, renal and endoscopy procedures worldwide. What are the underlying business or industry changes driving this perspective?Merit Medical Systems: Creating More Growth Engines (Rating Upgrade)
Summary Merit Medical Systems trades at 17-18x earnings with solid fundamentals, moderate leverage, and reasonable valuation, supporting an upbeat outlook. Q1 organic growth was on the lower end, but full-year guidance was maintained and even slightly raised for sales, reflecting recent M&A contributions. Growth engines include the View Point Medical acquisition and WRAPSODY, both expected to accelerate revenue and margin expansion into 2026. Despite softer organic growth and CEO transition, Merit's business remains resilient, with potential for re-rating as growth drivers materialize. Read the full article on Seeking Alpha
Tariffs And OEM Volatility Will Pressure Margins Yet Long Term Procedure Demand Will Support Progress
Catalysts About Merit Medical Systems Merit Medical Systems develops and sells medical devices used in vascular, oncology, cardiac, renal and endoscopy procedures worldwide. What are the underlying business or industry changes driving this perspective?MMSI: 2026 Guidance Execution And Margin Resilience Will Drive Future Upside
Analysts have nudged their price targets on Merit Medical slightly lower, with the updated fair value estimate moving from about $101.18 to $98.36 as they factor in modestly softer profit margin assumptions and a somewhat higher future P/E multiple, alongside recent target cuts and a downgrade tied to 2026 guidance uncertainty. Analyst Commentary Recent research on Merit Medical Systems highlights a mix of confidence in the business model and caution around execution against medium term targets, especially the 2026 outlook.MMSI: 2026 Margin Outlook And Guidance Will Drive Upside Potential
Analysts have trimmed the blended fair value estimate for Merit Medical Systems to about $101 from roughly $104, reflecting a lower projected price target that incorporates higher discount rates, slightly softer revenue growth assumptions, and a more moderate future P/E multiple, even as margin expectations improve. Analyst Commentary Recent Street research on Merit Medical Systems presents a mixed picture, with some analysts trimming targets or ratings on guidance uncertainty, while others still see room for valuation support based on execution and margins.We Like These Underlying Return On Capital Trends At Merit Medical Systems (NASDAQ:MMSI)
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Merit Medical: A Success Story That Keeps Getting Better
Summary Merit Medical continues to outperform, with the share price supported by on-target financial results, incremental M&A, and positive clinical data. The company's Wrapsody stent graft showed almost best-case clinical efficacy, positioning it to capture significant market share in dialysis graft occlusion procedures. Recent acquisitions, including EsophyX Z+ and Cook Medical’s lead management portfolio, enhance Merit’s product portfolio and offer longer-term synergies. CEO succession remains a concern, but could also prompt a bid for the company. Despite not being "super cheap", Merit’s strong execution, revenue growth, and margin leverage justify a positive rating, with potential for further valuation uplift. Read the full article on Seeking AlphaMerit Medical Systems: Solid Execution, Stretched Valuations
Summary Merit Medical Systems' stock is up 40% from last spring's lows, driven by strong Q3 results and positive analyst sentiment. The stock's rally has stalled recently. The company has also made a small acquisition in September and garnered a key FDA approval to close out 2024 on a high note. More upside ahead, or will the shares experience further profit-taking? An analysis of Merit Medical Systems follows in the paragraphs below. Read the full article on Seeking AlphaMerit Medical Systems - Impressive Momentum
Summary Merit Medical Systems has shown strong operating momentum this year, driven by organic growth and strategic acquisitions. Founder Fred Lampropoulos plans to retire by the end of 2025, as a well-planned succession alleviates concerns on that front. Recent acquisitions, including EndoGastric Solutions and Cook's Medical portfolio, enhance product offerings but are priced into the current high valuation. Despite positive momentum and trial results, the stock's high valuation warrants a cautious, wait-and-see approach. Read the full article on Seeking AlphaAktionärsrenditen
| MMSI | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 14.0% | 7.3% | -2.6% |
| 1Y | -1.8% | -15.9% | 14.3% |
Rendite im Vergleich zur Industrie: MMSI übertraf die Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -15.9 erzielte.
Rendite vs. Markt: MMSI hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 14.3 erzielte.
Preisvolatilität
| MMSI volatility | |
|---|---|
| MMSI Average Weekly Movement | 5.1% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: MMSI hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: MMSIDie wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1987 | 7,500 | Martha Aronson | www.merit.com |
Merit Medical Systems, Inc. entwirft, entwickelt, produziert und vermarktet medizinische Einwegprodukte für interventionelle, diagnostische und therapeutische Verfahren in den Vereinigten Staaten, China, Japan, Deutschland, Frankreich, dem Vereinigten Königreich und international. Das Unternehmen ist in zwei Segmenten tätig: Kardiovaskulär und Endoskopie. Das Unternehmen bietet Mikropunktur-Kits, angiografische Nadeln, Schleusen, Führungsdrähte und Sicherheitsprodukte; periphere Interventionsprodukte, die Angiografie-, Drainage-, Einführungs- und Embolotherapieprodukte umfassen; Onkologieprodukte, wie z. B. Produkte und Zubehör für die Biopsie von Weichgewebe; Produkte für die Herzintervention, bestehend aus Produkten für den kardialen Zugang, Angiographie, Elektrophysiologie und Herzrhythmusmanagement, Flüssigkeitsmanagement, hämodynamische Überwachung, Blutstillung und Intervention; und Produkte für die Wirbelsäule, einschließlich Wirbelkörperaugmentation, Radiofrequenzablation und Knochenbiopsie-Systeme.
Merit Medical Systems, Inc.'s Grundlagenzusammenfassung
| MMSI grundlegende Statistiken | |
|---|---|
| Marktanteil | US$4.82b |
| Gewinn(TTM) | US$139.34m |
| Umsatz(TTM) | US$1.54b |
Ist MMSI zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| MMSI Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$1.54b |
| Kosten der Einnahmen | US$791.39m |
| Bruttogewinn | US$751.05m |
| Sonstige Ausgaben | US$611.71m |
| Gewinn | US$139.34m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 2.34 |
| Bruttomarge | 48.69% |
| Nettogewinnspanne | 9.03% |
| Schulden/Eigenkapital-Verhältnis | 45.2% |
Wie hat sich MMSI auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/30 00:56 |
| Aktienkurs zum Tagesende | 2026/07/30 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Merit Medical Systems, Inc. wird von 22 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| null null | Baird |
| David Rescott | Baird |
| Michael Petusky | Barrington Research Associates, Inc. |